Quantitative Imaging of Cerebral Thromboemboli In Vivo

• DOI: 10.1161/strokeaha.117.016511
• Publication Date: 2017-04-22T01:10:47Z
• Authors: Dong-Eog Kim; Jeong-Yeon Kim; Dawid Schellinger...; Ju Hee Ryu; Su-Kyoung Lee; Sangmin Jeon; Ji Sung Lee; Jiwon Kim; Hee Jeong Jang; Jung E. Park; Eo Jin Kim; Ick Chan Kwon; Cheol-Hee Ahn; Matthias Nahrendorf; Kwangmeyung Kim
• Keywords: Metal Nanoparticles; X-Ray Microtomography; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; 0302 clinical medicine; Fibrinolytic Agents; Intracranial Embolism; Tissue Plasminogen Activator; Animals; Gold; Intracranial Thrombosis

Quantitative imaging for the noninvasive assessment of thrombolysis is needed to advance basic and clinical thrombosis-related research tailor tissue-type plasminogen activator (tPA) treatment stroke patients. We quantified evolution cerebral thromboemboli using fibrin-targeted glycol chitosan-coated gold nanoparticles microcomputed tomography, with/without tPA therapy.We injected thrombi into distal internal carotid artery in mice (n=50). Fifty-five minutes later, we nanoparticles, 5 after that, treated animals with or not (25 mg/kg). acquired serial tomography images 24 hours posttreatment.Thrombus burden at baseline was 784×103±59×103 μm2 group (n=42) 655×103±103×103 saline (n=8; P=0.37). Thrombus shrinkage began 0.5 1 hour therapy, a maximum initial rate change 4603±957 μm2/min. The lowered ≈61% level 2, followed by ≈29% ≈1% 2 3 24, respectively. Thus, 85% total over (≈500 μm2, equivalent 64% thrombus burden) occurred within first treatment. could be predicted around 1.5 hours. Saline associated significant changes burden. Infarct size smaller versus (18.1±2.3 45.8±3.3 mm2; P<0.01). correlated final (r=0.71; Time thrombolysis, completeness therapy were independent predictors infarct size.Thromboembolic efficacy can assessed serially, noninvasively, quantitatively high-resolution fibrin-binding nanoparticle agent.